2016 American Transplant Congress
Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression in order to further reduction of EVR and CNI was evaluated in clinical…2016 American Transplant Congress
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
Background:Use of an appropriate immunosuppressant is necessary for good graft survival in kidney transplantation (KTx). Currently, a prolonged-release formulation of tacrolimus (Graceptor or Adovagraf, Astellas…2016 American Transplant Congress
Are Random Tacrolimus Levels in the Emergency Department Costing You Money?
University of Illinois at Chicago, Chicago.
Purpose: Tacrolimus (TAC) is the most frequently used immunosuppressant in the USA today, with a narrow therapeutic index that requires frequent 12-hour trough monitoring and…2016 American Transplant Congress
Pharmacokinetic Evaluation of Astagraf XL® and Prograf® in Renal Transplant Candidates Following Laparoscopic Sleeve Gastrectomy.
Purpose: The impact of laparoscopic sleeve gastrectomy (LGS) on immunosuppressive drug pharmacokinetics (PK) is unknown. The purpose of this study was to evaluate PK following…2016 American Transplant Congress
Mycophenolate Mofetil Single Dose Pharmacokinetics Following Laparoscopic Sleeve Gastrectomy.
The influence of various metabolic surgery procedures on immunosuppressant pharmacokinetics (PK) is largely unknown. For laparoscopic sleeve gastrectomy (LSG) (currently the most common procedure) no…2016 American Transplant Congress
Patients with ESRD Due to Diabetes Have Higher Variability of Their Tacrolimus Levels and Worse Outcomes.
Imperial College Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom.
IntroductionNonadherence to immunosuppressants is associated with rejection and graft loss and nonadherence to antidiabetics is associated with poor glycaemic control leading to microvascular complications and…2016 American Transplant Congress
Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients.
Objective: The aim of this study was to assess if changing between two different formulations of generic tacrolimus ([tac] Mylan® and Dr. Reddy's Lab®) impacts…2016 American Transplant Congress
Evaluating the Influence of Liver Donor and Recipient Race on Tacrolimus Dose Requirements.
Einstein Medical Center, Philadelphia, PA.
Background: The majority of liver transplant recipients (LTR) receive tacrolimus (TAC) to prevent allograft rejection. Early establishment of therapeutic levels is imperative to efficacy. Several…2015 American Transplant Congress
Pharmacokinetics of Everolimus (EVL) in Elderly Recipients Under Low-Tacrolimus(TAC)/Everolimus in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly ( >60 years) recipients are being renal transplanted more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- Next Page »